Biomarker study for patients with metastatic colorectal cancer treated with anti-angiogenic agent using liquid biopsy
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000043890
- Lead Sponsor
- ippon Medical Scool
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Not provided
Having UGT1A1*6 homo, UGT1A1*28 homo, and UGT1A1*6*28 double hetero Contraindicated for anti-VEGF inhibitor. Previous treatment with irinotecan Previous treatment with ramucirumab or aflibercept History of severe drug hypersensitivity Pregnant women or women who may become pregnant. Men whose partners wish to become pregnant. Patients with serious complications (interstitial pneumonia or pulmonary fibrosis, renal failure, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension) Patients with pleural effusion or ascites requiring treatment Patients with peritoneal dissemination that is considered likely to cause intestinal obstruction. Active multiple cancers. Significant ECG abnormalities or clinically problematic heart disease (heart failure, myocardial infarction, angina pectoris, etc.) Having brain metastases. Patients with active multiple cancers with a disease-free interval of less than 5 years (cured basal cell carcinoma of the skin and cervical cancer, or gastric cancer, esophageal cancer, and colorectal pM cancer confirmed to be cured by endoscopic mucosal resection may be enrolled. FDG-PET scan is not necessary, but bone metastasis should not be detected. The physician in charge considers the patient unsuitable for participation in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method